Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Clovis Oncology Inc (NASDAQ:CLVS)

84.43
Delayed Data
As of Jul 31
 +0.47 / +0.56%
Today’s Change
35.33
Today|||52-Week Range
102.28
+50.77%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$3.2B

Company Description

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. The company has three product candidates in its clinical development pipeline: CO-1686, an oral epidermal growth factor receptor (EGFR), covalent inhibitor currently in Phase I/II development for the treatment of non-small cell lung cancer (NSCLC), in patients with initial activating EGFR mutations as well as the T790M primary resistance mutation; rucaparib, an oral, small molecule poly (ADP-ribose) polymerase (PARP) inhibitor currently in Phase II development for ovarian cancer, which includes the global ARIEL2 (Assessment of Rucaparib in Ovarian Cancer Phase 2 Trial) study; and lucitanib, which is commencing Phase II clinical trials for the treatment of breast and lung cancers. Clovis Oncology was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Contact Information

Clovis Oncology, Inc.
2525 28th Street
Boulder Colorado 80301
P:(303) 625-5000
Investor Relations:
(303) 625-5023

Employees

Shareholders

Mutual fund holders45.61%
Other institutional42.87%
Individual stakeholders18.94%

Top Executives

Patrick J. MahaffyPresident, Chief Executive Officer & Director
Erle T. MastChief Financial Officer, Secretary & Executive VP
Andrew R. AllenChief Medical Officer & EVP-Clinical Development
Gillian C. Ivers-ReadChief Regulatory Officer & Executive VP
Steven L. HoerterChief Commercial Officer & Executive VP